Monitoring of anticoagulation in aprotinin-treated patients during heart operation.

[1]  T. Ebels,et al.  Arterial revascularization with the right gastroepiploic artery and internal mammary arteries in 300 patients. , 1994, The Journal of thoracic and cardiovascular surgery.

[2]  W. van Oeveren,et al.  Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients. , 1994, Journal of cardiothoracic and vascular anesthesia.

[3]  N. Tabuchi,et al.  Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass , 1993 .

[4]  S. Westaby.  Aprotinin in perspective. , 1993, The Annals of thoracic surgery.

[5]  J. Fareed,et al.  Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. , 1993, The Annals of thoracic surgery.

[6]  F. Loop,et al.  Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. , 1992, The Annals of thoracic surgery.

[7]  R. Thisted,et al.  In vitro effects of aprotinin on activated clotting time measured with different activators. , 1992, The Journal of thoracic and cardiovascular surgery.

[8]  M. Yacoub,et al.  Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. , 1992, The Journal of thoracic and cardiovascular surgery.

[9]  J. E. Doran,et al.  Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.

[10]  W. van Oeveren,et al.  Increased anticoagulation during cardiopulmonary bypass by aprotinin. , 1990, The Journal of thoracic and cardiovascular surgery.

[11]  R. Catane,et al.  Tuftsin induces tissue factor-like activity in human mononuclear cells and in monocytic cell lines. , 1990, Blood.

[12]  Steven D. Carson,et al.  Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. , 1990, Blood.

[13]  D. Cosgrove,et al.  Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). , 1989, The Journal of thoracic and cardiovascular surgery.

[14]  W. van Oeveren,et al.  Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. , 1987, The Annals of thoracic surgery.

[15]  F. Spencer,et al.  Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. , 1981, Annals of surgery.

[16]  C. Kisker,et al.  Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. , 1978, The Annals of thoracic surgery.

[17]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. , 1975, The Journal of thoracic and cardiovascular surgery.

[18]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. , 1975, The Journal of thoracic and cardiovascular surgery.